ImmunicIMUX
Recorded

Immunic R&D Day 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration1 hr 57 minParticipants13

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

A few organizational remarks. Please note that all participants will be in listen-only mode, and this event is being recorded. After today's presentations, there will be an opportunity to ask questions. The Q&A session will be held at the end of the event. In addition to the Immunic team, our two experts will stay online and be available for questions. If you join the webcast via the Zoom platform, there are two ways to submit questions. You can either submit your questions in writing via the Q&A tool of the Zoom portal, or if you would like to speak with us directly, please use the raise hand function of the Zoom portal to queue your question. As always, before we begin, I would like to remind you that this presentation may contain forward-looking statements.

Operator

Such statements can be identified by words such as may, will, expect, anticipate, estimate, or words with a similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunic's actual results to differ materially from those discussed here. Please note that these forward-looking statements reflect Immunic's opinions only as of the date of this presentation, and it undertakes no obligation to revise or publicly release the result of any revision to these forward-looking statements in light of new information or future events. Please refer to Immunic's SEC filings for a more detailed description of the risk factors that may affect Immunic's results and these forward-looking statements. Let's move on to today's actual agenda.

Operator

I'm super excited that two internationally renowned experts will be speaking on the call today, Dr. Jiwon Oh from the University of Toronto, and Dr. Maria Pia Sormani from the University of Genoa in Italy. Moreover, we will have our Immunic management team presenting, including Erik Lundgren, CEO, Dr. Hella Kohlhof, CSO, Dr. Mike Panzara, CMO, and Jason Tardio, President and COO. During today's event, the group will discuss the key unmet needs in progressive MS and the persistent needs for innovative approaches to the development of therapies that target novel mechanisms associated with neurodegeneration and MS progression. Immunic management will highlight the potential expansion opportunity for vidofludimus calcium in progressive MS, including the clinical and scientific rationale supporting the initiation of a phase III progressive MS trial. With this, I would like to hand over to our CEO, Erik Lundgren, to kick things off.

Erik LundgrenCEO

Eric? Great. Thank you, Jessica, and thank you everyone who's joining us live and/or anyone who watches the recording after the fact.

Erik LundgrenCEO

Really appreciate your interest in Immunic, in vidofludimus calcium, and in our very important efforts in progressive MS. Next slide, please, Jessica. I'll be quick. I just want to set a little bit of the context here. It's an extraordinarily exciting time at Immunic. We're really in a pivot, so pivoting towards a fully integrated commercial company with a real laser focus on multiple sclerosis. While we're going to spend the vast majority of today talking about our efforts in progressive MS, which I think represents the greatest unmet need in multiple sclerosis, it would be remiss of me to not mention that we also have a very near-term catalyst in relapsing MS.

Erik LundgrenCEO

And so we have two phase III studies, the ENSURE-1 and ENSURE-2 studies that are reading out in December. Everything is on track for that. We look at that as a near-term value inflection point for the company. If those studies are successful, allow us to submit an NDA next year and reach the market in 2028 with a relapsing indication. That will allow us to really establish our presence commercially, further advance and mature the company, and ultimately get to profitability so that we can support the next value horizon, which is truly defined by the topic of today, which is progressive MS. This is, as I said already, arguably the largest unmet need in MS today, and it represents progress in this space, represents tremendous value for the MS community, most importantly for people living with MS, and of course, for the company as well.

Erik LundgrenCEO

So, truly excited about the moment that we're in here, sitting on the cusp of data for our relapsing indications and simultaneously preparing for and initiating our studies, our further study, phase III study in progressive MS. It really is an example of what we're trying to build here, which is a leading organization focused on MS and people living with the disease, both in terms of how we're building ourselves, but also, I think you'll see in the presentations today, a reflection of us really starting with the patient and listening to what they value, what they struggle with, and ultimately, what would be meaningful for advancing and improving their lives. Next slide, please, Jessica. As you can see here, we have a lot going on, but in green, we're going to be talking at the bottom of the slide.

Erik LundgrenCEO

You see our phase II progressive MS study called the CALLIPER study. This study has been fully read out, and Dr. Mike Panzara will walk through some of the detailed findings of that study that enrich our hypothesis and thesis around our ability to really meaningfully move the needle in progressive MS, and that phase II data is a big part of the basis of that confidence as we move into, as I said, a phase III study in progressive MS. That study is in preparation and being initiated now, with a plan for the first patients to be enrolled in the first half of next year. Next slide, please. Last setup here, as I walk through, right now, it's about building the foundation for a commercial organization laser-focused on MS. That work is happening as we speak.

Erik LundgrenCEO

In this middle period, following an FDA approval based on the ENSURE data set in relapsing disease, we start to scale. We really establish ourselves in the MS community. We're generating cash and getting to sustainability from an operating environment and balance sheet environment in that middle period, all setting up for and in preparation for becoming truly a global leader in MS on the back of both the ENSURE data, but also the progressive MS data that we'll talk about here. As I said, extraordinarily exciting time here at the company. We feel so privileged to have an asset like this and an opportunity like this to lean in to advance care across the full spectrum of multiple sclerosis. With that, let's get into the topic of the day. It is my distinct pleasure to have the opportunity to introduce Dr. Jiwon Oh.

Erik LundgrenCEO

Dr. Oh is a staff neurologist, scientist, and medical director of the BARLO MS Centre at St. Michael's Hospital at the University of Toronto. Her research focuses on developing advanced MRI techniques for the use in clinical settings, the development of large data sets, and of course, her work as a clinical trialist. She leads the MRI research program at St. Michael's Hospital and is the principal investigator on numerous local and international multi-center collaborative studies. Dr. Oh is deeply committed to caring for people with MS, educating future generations of clinicians and scientists, and contributing to scientific developments that will drive the MS field forward. So with that, it is my distinct pleasure to welcome Dr. Jiwon Oh.

Jiwon OhStaff Neurologist, Scientist, and Medical Director of the Barlo MS Program at St. Michael’s Hospital

Thank you, Erik, and hello, everybody. I am going to, in the next 10 minutes, just set the stage for much of the discussion today and talk about what the greatest unmet needs are in MS and how important progression is throughout the entire disease course. I would say in the last 10, 15 years, what is becoming abundantly clear in the MS field to MS neurologists, to people living with MS, as well as scientists, is that MS really is a disease spectrum. We used to think that relapsing disease was really what happened at the beginning of disease in almost everybody. There was really very little progression until much later stages of disease or in people who are initially diagnosed with primary progressive MS.

Jiwon OhStaff Neurologist, Scientist, and Medical Director of the Barlo MS Program at St. Michael’s Hospital

But in part because of the successes of our treatment of relapsing disease biology, we are recognizing more and more that MS really is a disease spectrum, and there is this huge overlap of both relapsing and progressive disease biologies from the very beginning of disease until the very end of disease. Because of this recognition, international think tank groups like the International Advisory Committee on Clinical Trials in MS is publishing papers like this, which suggest that we really need a new mechanism-driven framework to describe the entire MS disease course. Probably the best pieces of evidence that illustrate this concept of MS as a disease spectrum and that both relapsing and progressive disease biologies are at play across the entire disease course is this publication of the first systematic description of progression that is independent of relapsing activity, or PIRA, as we like to call it.

Jiwon OhStaff Neurologist, Scientist, and Medical Director of the Barlo MS Program at St. Michael’s Hospital

This was first done back in 2020 by Ludwig Kappos and colleagues, and this was actually a post-hoc analysis of the pivotal phase III clinical trials that looked at ocrelizumab versus interferon beta-1a in people with relapsing MS. Like most contemporary relapsing MS clinical trial populations, this was a relapsing MS population that was very early in the disease course, so within a few years of diagnosis. When these investigators looked at this concept of PIRA, which was essentially progression or disability worsening happening well outside of the context of any clinical relapse, they were actually surprised to see that despite the fact that in our heads we always think that progression really does not happen in people with relapsing MS, they found that actually PIRA happens very commonly in people with relapsing MS very early in the disease course.

Jiwon OhStaff Neurologist, Scientist, and Medical Director of the Barlo MS Program at St. Michael’s Hospital

When you look at the disability worsening events in these clinical trials that happened, the vast majority, so nearly 80%-90% of them, were due to PIRA. This was a bit of a moment in the field when we recognized that, you know what? Progression that happens outside of the context of relapses is not something that only happens in progressive forms of MS or in the later stages of disease. It absolutely happens and happens very frequently from the very beginning of the disease. In addition, when you look at contemporary MS clinical trials that looked at purely progressive forms of disease, again, we think if based on that prior framework, that in these people, there should be very little evidence of relapsing disease activity.

Jiwon OhStaff Neurologist, Scientist, and Medical Director of the Barlo MS Program at St. Michael’s Hospital

What we see, say in ORATORIO, that looked at primary progressive MS and ocrelizumab, EXPAND, that looked at SPMS and siponimod, and HERCULES, that recently looked at non-relapsing secondary progressive MS and tolebrutinib, when you look for gadolinium-enhancing lesions, which we think is the MRI equivalent of relapsing disease activity, you very clearly see that even when you're trying to look at purely progressive populations, you have actually a substantial portion of people that even at the beginning of the trial show evidence of relapsing disease activity based on MRI features. All of this shows us and clearly illustrates that MS is a disease spectrum and that both relapsing and progressive disease biologies happen across the entire disease spectrum. You might say then, what does this mean for the field?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day